All news

Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity

Alpha Vantage · Yahoo Finance · · AI-summarised by FinFlash

Moderna and Merck anticipate filing a U.S. application for their individualized cancer therapy, intismeran, by the end of the year, following positive Phase III melanoma results. Moderna views this therapy as a multibillion-dollar opportunity, estimating 22,000 U.S. patients could be eligible for adjuvant melanoma treatment.

Read original source

MRNA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.